48 citations,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
2 citations,
March 2021 in “Cutis” Some breast cancer treatments, like taxanes, can cause long-term hair loss.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
4 citations,
November 2021 in “Cancers” The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
Certain drugs can worsen hair loss in people prone to androgenetic alopecia.
19 citations,
July 1990 in “Cleveland Clinic journal of medicine” Androgen excess disorders in women were effectively treated with spironolactone, estrogen, and dexamethasone.
179 citations,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
67 citations,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
15 citations,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.
9 citations,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
1 citations,
January 2018 in “Springer eBooks” The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
3 citations,
November 2018 in “Oncology issues” Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
7 citations,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
53 citations,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
30 citations,
April 1997 in “European journal of endocrinology” The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.
43 citations,
April 2017 in “Experimental Dermatology” Female pattern hair loss has unclear causes, possibly involving genetics, hormones, and environment, and needs better treatments.
9 citations,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
February 2024 in “PloS one” Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
43 citations,
March 2019 in “JAMA Dermatology” Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.
February 2024 in “Biomedicines” Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.
90 citations,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
34 citations,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
25 citations,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
February 2013 in “Journal of The American Academy of Dermatology” There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.
1 citations,
September 2020 in “Pediatric Dermatology” Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.